Depo-Provera

Endometrial Hyperplasia, Endometriosis, Chronic Pain + 18 more

Treatment

7 FDA approvals

20 Active Studies for Depo-Provera

What is Depo-Provera

Medroxyprogesterone acetate

The Generic name of this drug

Treatment Summary

Medroxyprogesterone acetate (MPA) is a hormone-based drug that was approved by the FDA in 1959. Its main purpose is to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, and osteoporosis. It can also be used to reduce pain in endometriosis, manage vasomotor symptoms in menopause, and prevent pregnancy. MPA is also used to treat endometrial and renal carcinoma in palliative care.

Medroxyprogesterone Acetate

is the brand name

image of different drug pills on a surface

Depo-Provera Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Medroxyprogesterone Acetate

Medroxyprogesterone acetate

1959

139

Approved as Treatment by the FDA

Medroxyprogesterone acetate, also known as Medroxyprogesterone Acetate, is approved by the FDA for 7 uses such as Vasomotor Symptoms Associated With Menopause and Vulvo Vaginal Atrophy .

Vasomotor Symptoms Associated With Menopause

Used to treat Vasomotor Symptoms Associated With Menopause in combination with Conjugated estrogens

Vulvo Vaginal Atrophy

Used to treat Vulvo Vaginal Atrophy in combination with Conjugated estrogens

Postmenopausal Osteoporosis

Used to treat Postmenopausal Osteoporosis in combination with Conjugated estrogens

Hot flashes

Used to treat Menopause in combination with Conjugated estrogens

Hot Flashes

Used to treat Vasomotor Symptoms Associated With Menopause in combination with Conjugated estrogens

Osteoporosis, Postmenopausal

Used to treat Postmenopausal Osteoporosis in combination with Conjugated estrogens

Atrophic

Used to treat Vulvo Vaginal Atrophy in combination with Conjugated estrogens

Effectiveness

How Depo-Provera Affects Patients

Medroxyprogesterone acetate, or MPA, blocks hormones that help cells grow and can cause cell death in cancer cells. Depending on the form of MPA taken, its effects can last for up to a week. The drug is available in doses from 5mg daily to 1000mg a week, so it can be taken in a variety of ways. Unfortunately, long-term use of MPA can reduce bone density and lead to osteoporosis and fractures in the future - especially if taken during adolescence.

How Depo-Provera works in the body

Medroxyprogesterone acetate (MPA) works to prevent pregnancy by stopping the release of hormones that cause ovulation. It also thins the lining of the uterus. MPA reduces estrogen receptors in the endometrium, and can induce apoptosis in some cancer cell lines. It also works to inhibit certain GABA-A receptors.

When to interrupt dosage

The prescribed dosage of Depo-Provera is contingent upon the diagnosed condition, for example Hormonal Contraception, Amenorrhea and Postmenopausal Osteoporosis. The level of dosage is contingent upon the mode of administration (e.g. Tablet - Oral or Intramuscular) stated in the table hereunder.

Condition

Dosage

Administration

Endometriosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Chronic Pain

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Amenorrhea

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Osteoporosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

conjugated estrogen

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

hypoestrogenism

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Birth Control

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Endometriosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Endometrial Neoplasms

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Fracture

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hot flashes

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Osteoporosis, Postmenopausal

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Estrogen Replacement Therapy

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hot Flashes

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Uterine hemorrhage

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Atrophic

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hormonal Contraception

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Kidney Neoplasms

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Pharmaceutical Preparations

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Pharmaceutical Preparations

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Warnings

Depo-Provera Contraindications

Condition

Risk Level

Notes

Thromboembolism

Do Not Combine

Breast

Do Not Combine

Thrombophlebitis

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Breast

Do Not Combine

Breast Cancer

Do Not Combine

Stroke

Do Not Combine

Vascular Diseases

Do Not Combine

Thromboembolism

Do Not Combine

Liver Disease

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

suspected pregnancy

Do Not Combine

Disease

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Medroxyprogesterone Acetate may interact with Pulse Frequency

There are 20 known major drug interactions with Depo-Provera.

Common Depo-Provera Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Medroxyprogesterone acetate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Medroxyprogesterone acetate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Medroxyprogesterone acetate.

Alpelisib

Major

The metabolism of Alpelisib can be increased when combined with Medroxyprogesterone acetate.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Medroxyprogesterone acetate.

Depo-Provera Toxicity & Overdose Risk

The lowest toxic dose of medroxyprogesterone acetate in rats is greater than 6400mg/kg and in mice is greater than 16g/kg. Overdosing on MPA can cause symptoms such as nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and vaginal bleeding. If someone has been given too much of a MPA depo injection, they should seek medical help immediately.

image of a doctor in a lab doing drug, clinical research

Depo-Provera Novel Uses: Which Conditions Have a Clinical Trial Featuring Depo-Provera?

406 active clinical trials are currently assessing the potential of Depo-Provera to provide Osteoporosis, Amenorrhea and Hormonal Contraception relief.

Condition

Clinical Trials

Trial Phases

Endometriosis

27 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4

Osteoporosis

27 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Chronic Pain

130 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1

Endometrial Neoplasms

0 Actively Recruiting

Fracture

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

Pharmaceutical Preparations

0 Actively Recruiting

Birth Control

22 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Estrogen Replacement Therapy

0 Actively Recruiting

Hormonal Contraception

0 Actively Recruiting

Endometriosis

2 Actively Recruiting

Phase 4, Not Applicable

Hot Flashes

4 Actively Recruiting

Not Applicable, Phase 2, Phase 1

Kidney Neoplasms

35 Actively Recruiting

Phase 1, Phase 3, Phase 2, Not Applicable

conjugated estrogen

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

hypoestrogenism

1 Actively Recruiting

Phase 4

Atrophic

4 Actively Recruiting

Phase 4, Not Applicable

Amenorrhea

0 Actively Recruiting

Pharmaceutical Preparations

0 Actively Recruiting

Endometrial Hyperplasia

4 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Depo-Provera Reviews: What are patients saying about Depo-Provera?

5

Patient Review

8/26/2022

Depo-Provera for Endometriosis

This shot took some time to work for me, but it was well worth the wait. I have endometriosis and had already undergone surgery when I started this treatment. The first three months were tough with pain, bleeding, and mood swings, but after getting the second shot things really improved. Everyone is different, but don't expect this medication to fix all your problems in a month. Give it some chance to work its magic!

5

Patient Review

8/21/2022

Depo-Provera for Birth Control

I no longer have to deal with periods, which is amazing because they used to be really painful and heavy before I started this medication. They were affecting my iron levels as well, and since I already had anemia, I had to get four infusions of iron every week for weeks on end.

4.3

Patient Review

6/20/2022

Depo-Provera for Endometriosis

I've started taking depo to help with the pain and heavy bleeding I experience during my period. So far, I'm really pleased with it. I haven't had any side effects or bleed through since starting it a few weeks ago. Fingers crossed that it continues to go well!

4.3

Patient Review

9/24/2022

Depo-Provera for Birth Control

I've been on Depo-Provera for 11 years and, while there are some drawbacks like having to go to the doctor every 3 months and experiencing shakes, anxiety, heart palpitations, etc., I never have to worry about my period anymore. That being said, I am concerned about the bone loss that this is said to cause.

4

Patient Review

10/31/2022

Depo-Provera for Birth Control

I started the depo shot in September of 2021, and I was on it for over a year. Unfortunately, during that time I experienced extremely heavy and painful periods. Additionally, my sex drive plummeted while I was on this medication. Thankfully, I've since switched to the pill which has been much better for me.

3

Patient Review

10/17/2022

Depo-Provera for Birth Control

I gained a lot of weight while using this medication, but fortunately lost all of it after I stopped taking it. It was always very effective at preventing pregnancy, but the side effects were really terrible. I wouldn't recommend it to anyone.

2.7

Patient Review

9/1/2022

Depo-Provera for Birth Control

I started the depo shot on April 21st and experienced spotting every day for the next three months. I'm now in September and still haven't gotten my period back. This birth control method really messed up my body.

2.3

Patient Review

8/5/2022

Depo-Provera for Birth Control

I lost 20 pounds in 6 months while on the depo shot, but I started experiencing a whole host of other problems like PCOS, hair loss, anxiety, and depression. I stopped it a month ago and hope my health will improve.

2

Patient Review

1/31/2022

Depo-Provera for Birth Control

I was on my period for almost three weeks straight, which finally stopped last night. It was an incredibly difficult and frustrating experience; I felt dizzy, bloated, had mood swings, and low self-esteem the entire time. I would never get this shot again.

1

Patient Review

3/13/2022

Depo-Provera for Birth Control

I took the shot once and started experiencing weight gain, mood swings, and depression. My period also began about a week after taking it and I've been bleeding ever since--two periods a month, heavy and with daily spotting. If you're doubting whether or not to take this medication, trust your gut instinct.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about depo-provera

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Depo-Provera cause weight gain?

"Depot Provera (DMPA) is a commonly used and effective form of birth control, however, most studies confirm that weight gain is a common side effect for those who use it. DMPA is more likely to cause weight gain than other methods like the pill or an IUD."

Answered by AI

How long does Depo-Provera take to work?

"If you want to be protected from pregnancy as soon as possible, you should get your first birth control shot within the first 7 days after the start of your period. If you wait longer than that, it will take a full week for the shot to become effective. To be safe, you should use a backup method of contraception, like condoms, for the first week after getting the shot."

Answered by AI

What is the most common side effect of Depo-Provera?

"The shot can also make your periods lighter, heavier, or more frequent.

The birth control shot is most commonly associated with irregular bleeding. You may experience bleeding problems for 6 to 12 months after you first begin using the shot. The shot can also make your periods lighter, heavier, or more frequent."

Answered by AI

What does Depo do to your body?

"The Depo-Provera shot affects ovulation by preventing an egg from being released from a woman's ovary. It also thickens the cervical mucus, making it difficult for sperm to reach the egg."

Answered by AI

Clinical Trials for Depo-Provera

Image of UCI Health Susan Samueli Integrative Health Institute in Irvine, United States.

Biofield Therapy for Cancer

18+
All Sexes
Irvine, CA

Cancer treatment with immunotherapy is often associated with symptoms such as fatigue, pain, and emotional distress, which may affect patients' daily functioning and quality of life. Additional supportive care approaches are being studied to better understand their potential role in supporting these symptoms. The purpose of this study is to learn whether a biofield therapy, called Reiki may help to support adults with cancer who are receiving immunotherapy and currently struggling with fatigue. Reiki is a non-invasive complementary therapy delivered by a trained practitioner who places their hands lightly near the body. It is intended to promote relaxation and support general well-being. Reiki is used as a supportive practice and is not considered a medical treatment or replacement for standard care. The secondary goal of this study is to evaluate the feasibility of delivering Reiki in this clinical setting. This includes examining recruitment, retention, adherence to study procedures, and overall participant engagement. Lastly, the third aim is to explore participants' experiences with Reiki through guided interviews. Participants enrolled in this study will first be asked to participate in a one-hour, one-on-one interview about their experiences with cancer treatment, their symptoms, and their thoughts about integrative care practices such as Reiki. After the interview, they will be randomly assigned to one of two groups: Immediate Reiki Group: If participants are assigned to this group, they will receive six weekly, in-person 30-minute Usui Reiki sessions from a Reiki master at the Susan Samueli Integrative Health Institute. Before and after each session, participants will complete questionnaires about fatigue, pain, and stress. At the first and final sessions, a small blood sample will be collected to measure inflammatory biomarkers, and Electroencephalogram (EEG) hyperscanning will be conducted to measure brain activity and connectivity between the participant and the practitioner. Four weeks after the final session, they will complete the questionnaires again, followed by a short satisfaction survey about their experience. Waitlist Group: If they are assigned to the waitlist group, they will first complete a 6-week observation period that includes brief weekly fatigue questionnaires and two in-person 30-minute sessions with EEG measurements at Week 1 and Week 6. This will be followed by a 4-week period with no sessions, after which they will complete questionnaires about fatigue, pain, and psychological distress. Participants will then begin the same six weekly, in-person 30-minute sessions described above. As with the Immediate Group, they will complete questionnaires before and after each session. At the first and final sessions, a small blood sample will be collected and EEG hyperscanning will be conducted. At the end of the study, participants will also complete a short satisfaction survey about their experience. The investigators hypothesize that participants receiving Reiki will report improvements in symptoms and well-being compared to those not yet receiving Reiki, and that the intervention will be feasible to implement and acceptable to participants.

Recruiting
Has No Placebo

UCI Health Susan Samueli Integrative Health Institute (+1 Sites)

Image of Vanderbilt Center for Women's Health in Nashville, United States.

Podcast for Pelvic Pain

18+
Female
Nashville, TN

The purpose of this research study is to study the impact of an educational podcast on pelvic pain. If you decide to take part in this research, you may receive the standard treatment for pelvic pain, or you may receive the standard treatment plus access to an educational podcast series. You will be randomly assigned to receive access to the podcast or to receive standard care. If you are assigned to receive access to the podcast, participating in this research will involve listening to a podcast series. All participants will complete three ten-minute online surveys over the course of 6 months. Reasons you may choose to participate in this research are if you want to learn more about pelvic pain and possible benefits of listening to the podcast, such as improved quality of life, reduced stigma, or increased satisfaction with your medical care.

Recruiting
Has No Placebo

Vanderbilt Center for Women's Health

Have you considered Depo-Provera clinical trials?

We made a collection of clinical trials featuring Depo-Provera, we think they might fit your search criteria.
Go to Trials
Image of Albert Einstein College of Medicine in The Bronx, United States.

Vaginal Estradiol vs Moisturizer for Menopause in Women with HIV

40 - 70
Female
The Bronx, NY

This is a research study about the effects of vaginal estradiol compared to moisturizer on vaginal symptoms of menopause and the microbiome in women with HIV. This research study aims to understand how vaginal products affect the aging of the female genital tract in women living with HIV who are menopausal or perimenopausal and have vaginal or urinary symptoms. There is a comparison group of women who are living without HIV. Participants with HIV and vaginal or urinary menopausal symptoms (e.g., dryness, irritation, soreness, itching, pain with sex, dysuria, urgency, or frequent urinary tract infections) will be asked to apply vaginal estradiol or a vaginal moisturizer (Replens). Participants who have vaginal or urinary menopausal symptoms and do not have HIV will receive vaginal estradiol.

Phase 4
Waitlist Available

Albert Einstein College of Medicine

Kerry J Murphy, MD

Have you considered Depo-Provera clinical trials?

We made a collection of clinical trials featuring Depo-Provera, we think they might fit your search criteria.
Go to Trials
Image of Resound Research for Reproductive Health, a project of the Tides Center in San Francisco, United States.

"Vasectomy: Right for Me?" Decision Aid for Birth Control

21 - 55
Male
San Francisco, CA

The goal of this trial is to learn if a web-based decision aid designed to provide evidence-based information about vasectomy and other birth control options helps improve users' decision-making about birth control. The main questions it aims to answer are: * Do people who use the decision aid have better knowledge about vasectomy? * Do people who use the decision aid have lower conflict with their decision? Participants will: * Use the decision aid (if they are assigned to the intervention arm). * Answer survey questions about their knowledge, decision-making, interest in vasectomy, and healthcare navigation experiences.

Waitlist Available
Has No Placebo

Resound Research for Reproductive Health, a project of the Tides Center (+1 Sites)

Sonya Borrero, MD, MS

Image of Donald Berman Maimonides Maimonides Geriatric Centre in Montreal, Canada.

Virtual Reality for Pain

Any Age
All Sexes
Montreal, Canada

This study will test whether immersive virtual reality (iVR) can reduce pain and discomfort during wound care for residents living in long-term care (LTC). Pressure ulcers are common and painful among older adults, and dressing changes often cause additional distress. Up to 20 residents at the Donald Berman Maimonides Geriatric Centre will use virtual reality headsets during routine wound care. The headsets display calm, low-stimulus scenes (e.g., puppies in a meadow) designed to distract and comfort participants. Each participant will take part for six weeks in three phases: * Two weeks of usual wound care (baseline) * Two weeks using virtual reality during wound care (intervention) * Two weeks of usual care again (washout) Pain will be assessed using validated tools, and the research team will also observe agitation, mood, and other behavioral indicators. Nursing staff will provide feedback on feasibility and acceptability of iVR use in LTC settings.

Recruiting
Has No Placebo

Donald Berman Maimonides Maimonides Geriatric Centre

Machelle Wilchesky, PhD

Image of University of Iowa/Holden Comprehensive Cancer Center in Iowa City, United States.

Progestins for Endometrial Cancer

18+
Female
Iowa City, IA

This phase II trial tests compares the effect of progestins, megestrol acetate to micronized progesterone, in treating patients with endometrial cancer and precancers of the uterus (atypical endometrial hyperplasia) before surgery. Progestins, similar to the natural hormone progesterone, are approved drugs used in birth control and hormone replacement pills, and some can treat uterine endometrial cancers. In the initial comparison of this rotating umbrella trial, megestrol acetate, a progestin, will be compared to micronized progesterone, a form of natural progesterone that is a hormone produced by body normally. Hormone therapy using megestrol acetate and micronized progesterone may be effective in treating patients with endometrial cancer or atypical endometrial hyperplasia before surgery, and understanding the tissue effects of each agent on the malignant endometrium will uncover novel mechanistic and biomarker data to understand how best to advanced hormone therapy for endometrial cancer.

Phase 2
Waitlist Available

University of Iowa/Holden Comprehensive Cancer Center (+3 Sites)

Carolyn Y Muller

Have you considered Depo-Provera clinical trials?

We made a collection of clinical trials featuring Depo-Provera, we think they might fit your search criteria.
Go to Trials